16 April, 2014 12:51 IST
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS (19-NOV-12)
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).

Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Live News
Sensex turns negative; IT stocks fall - 16-Apr-2014 12:47
INR weakens against USD, down marginally to 60.24 - 16-Apr-2014 12:42
RBI governor to hold rates on June 1: BofA-ML - 16-Apr-2014 12:30
Ind-Ra rates Usha Martin's additional bank loans - 16-Apr-2014 12:28
Jubilant FoodWorks rises as RBI hikes FII limit to 55% - 16-Apr-2014 12:25
Sameet Chavan on Biocon, Axis Bank and JSW Steel - 16-Apr-2014 12:25
Ind-Ra withdraws Sunil Hitech's ratings - 16-Apr-2014 12:24
Tata Power expands green energy power generation capacity by 646.7 MW - 16-Apr-2014 12:19
Punj Lloyd climbs on new order worth Rs 32.54 bn - 16-Apr-2014 12:17
RCom hikes tariffs by up to 20% - 16-Apr-2014 12:15
Glenmark gains on final ANDA approval for Eszopiclone - 16-Apr-2014 12:14
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
 Post Comment
Name Email
Security Code type   qknzfk into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Forums  |   E-mail  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer